Expert Interview
Evaluating Phase III PSMAddition Results for Pluvicto in PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer from Novartis
Ticker(s): NVSA medical oncologist or nuclear medicine specialist with expertise in genitourinary cancers, specifically prostate cancer. Ideally, the expert is familiar with radioligand therapy (RLT), PSMA-targeting agents, and has experience running or analyzing Phase III clinical trials.
The PSMAddition trial showed a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS). How does this shape the therapeutic landscape for patients in the hormone-sensitive setting, particularly compared to existing options?
Added By: slingshot_insightsPluvicto is already approved in metastatic castration-resistant prostate cancer (mCRPC). How meaningful is this data showing benefit in an earlier-stage population, and what are the key considerations in moving RLT up the treatment line?
Added By: slingshot_insightsRadioligand therapy (RLT) offers a distinct mechanism via targeted radioactive emission. In what ways does this differ functionally from traditional therapies like ADT or ARPIs in controlling hormone-sensitive disease?
Added By: slingshot_insightsWhile rPFS showed robust benefit, overall survival (OS) data remain immature. In your view, how do regulators and clinicians weigh rPFS as a surrogate for meaningful benefit in this disease setting?
Added By: slingshot_insightsGiven Pluvicto's expanding role, how do you envision PSMA-PET and molecular diagnostics evolving to better select patients for earlier intervention with RLT?
Added By: slingshot_insightsThe PSMAddition trial allowed crossover to Pluvicto upon progression. How might this influence the interpretation of OS data and its relevance for clinical decision-making?
Added By: slingshot_insightsDo we have any early insights into the safety profile of Pluvicto in mHSPC versus mCRPC populations? Are tolerability considerations different when treating earlier in the disease course?
Added By: slingshot_insightsNovartis is scaling its RLT manufacturing capacity globally. How crucial is manufacturing resilience and geographic reach to meeting the projected demand if Pluvicto becomes standard-of-care earlier in treatment?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
